About Us
Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprietary technologies, we are developing a robust pipeline of AXC candidates with the potential to address unmet medical needs for new treatment options.
